Skip to main content
Premium Trial:

Request an Annual Quote

Lexicon Licenses Gene Targeting Tech to Aventis

NEW YORK, April 22 - Lexicon Genetics said today it has non-exclusively licensed rights to its gene targeting technologies to Aventis, for use in the pharmaceutical company's internal research.


Lexicon, of The Woodlands, Texas, uses gene knockout technology in mammals to discovery gene function and utility of genes. It holds patents on these technologies.


The company did not disclose the financial terms of the agreement.


Pfizer, GlaxoSmithKline, Merck, and Millennium Pharmaceuticals are among the other licensees of Lexicon's technology.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.